CO5050296A1 - Derivados de 1-arenosulfonil-2-arilo-pirrolidina y de piperidina - Google Patents

Derivados de 1-arenosulfonil-2-arilo-pirrolidina y de piperidina

Info

Publication number
CO5050296A1
CO5050296A1 CO00020380A CO00020380A CO5050296A1 CO 5050296 A1 CO5050296 A1 CO 5050296A1 CO 00020380 A CO00020380 A CO 00020380A CO 00020380 A CO00020380 A CO 00020380A CO 5050296 A1 CO5050296 A1 CO 5050296A1
Authority
CO
Colombia
Prior art keywords
lower alkyl
phenyl
arenosulfonil
pirrolidine
piperidine
Prior art date
Application number
CO00020380A
Other languages
English (en)
Inventor
Vincent Mutel
Eric Vieira
Jurgen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO5050296A1 publication Critical patent/CO5050296A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Compuestos de fórmula general:en donde R1 significa hidrógeno, alquilo inferior o hidroxilo-alquilo inferior;R2 significa furilo, tienilo, piridilo o fenilo, el cual está opcionalmente sustituido por 1 a 3 substituyentes, seleccionados de alquilo inferior, alcoxilo inferior, halógeno, ciano, CF3 ó -N(R4 )2 ;R3 significa naftilo o fenilo, el cual está opcionalmente sustituido con 1 a 3 substituyentes, seleccionados de aquilo inferior, alcoxilo inferior, halógeno, acetilo, ciano, hidroxilo-alquilo inferior, -CH2 -morfolin-4-ilo, alquilo inferior oxi-alquilo inferior, alquilo inferior -N(R4 )2 ó CF3 ;R4 significa, independientemente entre sí hidrógeno o alquilo inferior, con la excepción de la (RS)-2-fenil-1-(toluen-4-sulfonil)-pirrolidina y (RS)-1-(toluen-4-sulfonil)-2-p-tolil-pirrolidinaasí como sus sales farmacéuticamente aceptables.
CO00020380A 1999-03-25 2000-03-22 Derivados de 1-arenosulfonil-2-arilo-pirrolidina y de piperidina CO5050296A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99106004 1999-03-25

Publications (1)

Publication Number Publication Date
CO5050296A1 true CO5050296A1 (es) 2001-06-27

Family

ID=8237852

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00020380A CO5050296A1 (es) 1999-03-25 2000-03-22 Derivados de 1-arenosulfonil-2-arilo-pirrolidina y de piperidina

Country Status (34)

Country Link
US (1) US6284785B1 (es)
EP (1) EP1165510B1 (es)
JP (1) JP3590589B2 (es)
KR (1) KR100452648B1 (es)
CN (1) CN1150165C (es)
AR (1) AR028817A1 (es)
AT (1) ATE305451T1 (es)
AU (1) AU765212B2 (es)
BR (1) BR0009278A (es)
CA (1) CA2368418C (es)
CO (1) CO5050296A1 (es)
CZ (1) CZ20013402A3 (es)
DE (1) DE60022867T2 (es)
DK (1) DK1165510T3 (es)
ES (1) ES2249249T3 (es)
HK (1) HK1044944B (es)
HR (1) HRP20010682A2 (es)
HU (1) HUP0200284A3 (es)
IL (1) IL145301A0 (es)
JO (1) JO2274B1 (es)
MA (1) MA26779A1 (es)
MX (1) MXPA01009623A (es)
MY (1) MY125295A (es)
NO (1) NO319948B1 (es)
NZ (1) NZ514037A (es)
PE (1) PE20001583A1 (es)
PL (1) PL204436B1 (es)
RU (1) RU2248350C2 (es)
SI (1) SI1165510T1 (es)
TR (1) TR200102789T2 (es)
TW (1) TW575561B (es)
WO (1) WO2000058285A1 (es)
YU (1) YU67601A (es)
ZA (1) ZA200107689B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589978B2 (en) 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
US20040267010A1 (en) * 2001-02-02 2004-12-30 Forbes Ian Thomson Sulfonamide compounds, their preparation and use
TW200302717A (en) * 2002-02-06 2003-08-16 Schering Corp Novel gamma secretase inhibitors
WO2005030128A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Pyrazole modulators of metabotropic glutamate receptors
CA2567343A1 (en) * 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
JP5173192B2 (ja) 2004-09-30 2013-03-27 武田薬品工業株式会社 プロトンポンプ阻害薬
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
US7977488B2 (en) 2005-08-30 2011-07-12 Takeda Pharmaceutical Company Limited 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
NZ591793A (en) 2008-08-27 2012-11-30 Takeda Pharmaceutical Substituted 1-(4-fluoro-5-(2-fluoropyridin-3-yl)-1-((pyrindin-2-yl)sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine compounds
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
US10603313B2 (en) 2017-07-31 2020-03-31 Chiromics, LLC Allosteric modulators of the mu opioid receptor
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2685325B1 (fr) * 1991-12-20 1994-02-04 Adir Cie Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
GB9612884D0 (en) * 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
PE20001583A1 (es) 2001-01-15
ES2249249T3 (es) 2006-04-01
BR0009278A (pt) 2001-12-26
DE60022867T2 (de) 2006-06-22
KR20010108403A (ko) 2001-12-07
MXPA01009623A (es) 2002-05-06
ZA200107689B (en) 2002-12-18
CN1150165C (zh) 2004-05-19
HRP20010682A2 (en) 2002-10-31
PL350679A1 (en) 2003-01-27
MY125295A (en) 2006-07-31
JP3590589B2 (ja) 2004-11-17
EP1165510A1 (en) 2002-01-02
CA2368418C (en) 2009-03-10
SI1165510T1 (sl) 2005-12-31
MA26779A1 (fr) 2004-12-20
JP2002540191A (ja) 2002-11-26
IL145301A0 (en) 2002-06-30
US6284785B1 (en) 2001-09-04
TW575561B (en) 2004-02-11
AR028817A1 (es) 2003-05-28
EP1165510B1 (en) 2005-09-28
RU2248350C2 (ru) 2005-03-20
HUP0200284A3 (en) 2003-04-28
HUP0200284A2 (en) 2002-06-29
AU765212B2 (en) 2003-09-11
YU67601A (sh) 2004-09-03
AU3291500A (en) 2000-10-16
ATE305451T1 (de) 2005-10-15
TR200102789T2 (tr) 2002-04-22
HK1044944B (zh) 2004-10-21
NO20014617D0 (no) 2001-09-24
WO2000058285A1 (en) 2000-10-05
CZ20013402A3 (cs) 2002-03-13
JO2274B1 (en) 2005-04-07
DK1165510T3 (da) 2006-02-06
KR100452648B1 (ko) 2004-10-12
NO319948B1 (no) 2005-10-03
NO20014617L (no) 2001-09-24
NZ514037A (en) 2004-01-30
PL204436B1 (pl) 2010-01-29
CA2368418A1 (en) 2000-10-05
CN1345311A (zh) 2002-04-17
DE60022867D1 (de) 2006-02-09
HK1044944A1 (en) 2002-11-08

Similar Documents

Publication Publication Date Title
CO5050296A1 (es) Derivados de 1-arenosulfonil-2-arilo-pirrolidina y de piperidina
ATE389635T1 (de) Pharmazeutisch wirksame piperidinderivate
NO20051260L (no) Arylsubstituerte diazabicykloalkaner som nikotinacetylcholinagonister
NO20054852L (no) GFAT inhibitorer
EA200500017A1 (ru) Новые соединения
ES2193990T3 (es) Derivados de purina.
IS7718A (is) Pýrrólídíndíónútskipt píperídín-þalasón sem PDE4 tálmar
AR053329A1 (es) Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
DE69819173D1 (de) Indole und 2,3-dihydroindolderivate, ihre herstellung und verwendung
ATE465146T1 (de) 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren
DK1131315T3 (da) Polyhydroxylerede heterocykliske derivater som antikoagulanter
IS2754B (is) @@oxó@@@pýrrólidín@afleiða@og@lyfjafræðileg@notkun@hennar
ATE260275T1 (de) Substituierte thien-3-yl- sulfonylamino(thio)carbonyl-triazolin(thi)one
MY126139A (en) Piperidine compounds for use as ccr-3 inhibitors
NO20075734L (no) Tiofenforbindelser og trombopoietin reseptoractivatorer
NO20072753L (no) 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer
TR200403436T2 (tr) Kristalin 1-metilkarbapenem türevleri.
CY1112449T1 (el) Υποκατεστημενα ν-βενζο [d] ισοξαζολ-3-υλ-αμινο παραγωγα ως αναστολεις υποδοχεων mglur5, σεροτονινης-(5-ητ) και νοραδρεναλινης και η χρηση αυτων για την παραγωγη φαρμακων
ES2177275T3 (es) Derivados de oxadiazolina y su uso como insecticidas.
PE20050442A1 (es) Derivados de 8-azoniabiciclo[3.2.1]octano como antagonistas de receptores muscarinicos de la acetilcolina
PE20040701A1 (es) Derivados de indolinona sustituidos en posicion 6 y su preparacion como medicamentos
ATE408610T1 (de) Alkyl-und piperidin-substitutierte benzimidazol- derivate
ECSP045176A (es) Derivados de 5-(piridin-3-il)-1-azabiciclo[3.2.1]octano, su preparacion y su aplicación en terapeutica
PE20040160A1 (es) 1,2-dihidropirazol-3-onas que controlan citoquinas inflamatorias
TR200401488T4 (tr) CNS bozukluklarının tedavisinde faydalı indol türevleri